Related Experiment Video

Updated: Mar 31, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Association of Flavin Monooxygenase Gene E158K Polymorphism with Chronic Heart Disease Risk

O Yu Bushueva1, I V Bulgakova2, V P Ivanov2

  • 1Department of Biology, Medical Genetics, and Ecology, Kursk State Medical University, Kursk, Russia. olga.bushueva@inbox.ru.

Bulletin of Experimental Biology and Medicine
|November 1, 2015
PubMed

Insights

The FMO3 gene E158K polymorphism increases chronic heart disease risk in women with the 158KK genotype. This genetic variation is a key predictor of heart disease predisposition specifically in females.

Area of Science:

  • Genetics and Cardiovascular Health

Background:

  • Chronic heart disease (CHD) poses a significant global health burden.
  • Genetic factors, including specific gene polymorphisms, are increasingly recognized as contributors to CHD risk.
  • The Flavin-containing monooxygenase 3 (FMO3) gene plays a role in xenobiotic metabolism, potentially influencing cardiovascular health.

Purpose of the Study:

  • To investigate the association between the FMO3 gene E158K polymorphism and the risk of chronic heart disease.
  • To determine if this polymorphism presents a differential risk in men versus women.

Main Methods:

  • Polymerase Chain Reaction (PCR) was employed to identify genotypes.
  • Restriction Fragment Length Polymorphism (RFLP) analysis was utilized to analyze the FMO3 E158K polymorphism.
  • Statistical analysis was performed to correlate genotypes with CHD risk.

Main Results:

  • The homozygous 158KK genotype of the FMO3 gene was significantly associated with an elevated risk of chronic heart disease in women.
  • No significant association was observed between the FMO3 gene E158K polymorphism and chronic heart disease risk in men.
  • The FMO3 E158K polymorphism emerged as a significant predictor of chronic heart disease predisposition in the female population.

Conclusions:

  • The FMO3 gene E158K polymorphism, particularly the 158KK genotype, represents a specific risk factor for chronic heart disease in women.
  • This finding highlights the importance of considering sex-specific genetic predispositions in cardiovascular disease research and clinical practice.
Keywords:
associationchronic heart diseaseflavin-containing monooxygenase 3

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.5K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.0K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
77
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
960
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
123